Advertisement

Antikoagulantien und Thrombozytenaggregationshemmer

  • Ulrich Schwabe

Zusammenfassung

Die Verordnungen der Thrombozytenaggregationshemmer sind auch 2003 deutlich angestiegen (+11%). Führender Vertreter ist weiterhin mit großem Abstand die niedrig dosierte Acetylsalicylsäure. Verstärkt gewachsen ist die Verordnung des ADP-Rezeptorantagonisten Clopidogrel (+29 %). Bei den Antikoagulantien sind Vitamin-K-Antagonisten (Phenprocoumon, Warfarin) und niedermolekulare Heparine in etwa gleichem Ausmaß (14–15%) angestiegen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Albers GW, Amarenco P (2001): Combination therapy with Clopidogrel and aspirin. Can the CURE results be extrapolated to cerebrovascular patients? Stroke 32: 2948–2949.PubMedCrossRefGoogle Scholar
  2. Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001(4): CD 001342.Google Scholar
  3. Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.CrossRefGoogle Scholar
  4. Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH for the CLASSICS Investigators (2000): Double-blind study of the safety of Clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102: 624–629.PubMedCrossRefGoogle Scholar
  5. Born GVR, Collins R (1997): Aspirin versus Clopidogrel: the wrong question? Lancet 349: 806–807.PubMedCrossRefGoogle Scholar
  6. CAPRIE Steering Committee (1996): A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.CrossRefGoogle Scholar
  7. De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080.PubMedCrossRefGoogle Scholar
  8. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and Clopidogrel compared with Clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337.PubMedCrossRefGoogle Scholar
  9. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sei 143:1–13.CrossRefGoogle Scholar
  10. Eikelboom JW, Anand SS, Maimberg K, Weitz JI, Ginsberg JS, Yusuf S (2000): Unfrac-tionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355:1936–1942.PubMedCrossRefGoogle Scholar
  11. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650–1655.CrossRefGoogle Scholar
  12. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.CrossRefGoogle Scholar
  13. Gorelick PB, Born GVR, d’Agostino RB, Hanley DF Jr, Moye L, Pepine CJ (1999): Therapeutic benefit. Aspirin revisited in light of the introduction of Clopidogrel. Stroke 30:1716–1721.PubMedCrossRefGoogle Scholar
  14. Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 67:10–14.PubMedCrossRefGoogle Scholar
  15. Gum PA, Kottke-Marchant K, Poggio ED, et al. (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230–235.PubMedCrossRefGoogle Scholar
  16. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321: 501–507.PubMedCrossRefGoogle Scholar
  17. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003): Aspirin and Clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med 163:1145–1153.PubMedCrossRefGoogle Scholar
  18. Keng TB (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 114: 394–396.PubMedCrossRefGoogle Scholar
  19. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334: 682–687.PubMedCrossRefGoogle Scholar
  20. Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607.PubMedCrossRefGoogle Scholar
  21. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL et al. (1998): A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339:1665–1671.PubMedCrossRefGoogle Scholar
  22. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D et al. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677–681.PubMedCrossRefGoogle Scholar
  23. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Katarajan MK et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358:527–533.PubMedCrossRefGoogle Scholar
  24. Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930.PubMedCrossRefGoogle Scholar
  25. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S et al. (1999): Effectiveness of Clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99:2364–2366.PubMedCrossRefGoogle Scholar
  26. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345:494–502.CrossRefGoogle Scholar
  27. Van der Heijden JF, Hutten BA, Büller HR, Prins MH (2002): Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Revies). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.Google Scholar
  28. Walenga JM (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105:401–405.PubMedCrossRefGoogle Scholar
  29. Wenzel E, Keller-Stanislawski B, Tiaden JD, Mörsdorf S, Pindur G, Graul A, Seyfert UT (1999): Antithrombotische, blutstillende und antianämische Mittel. In: Müller-Oerlinghausen B, Lasek R, Düppenbecker H, Munter K-H (Hrsg): Handbuch der unerwünschten Arzneimittelwirkungen. Urban & Fischer, München.Google Scholar
  30. White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematoll 21: 12–20.CrossRefGoogle Scholar
  31. Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159:1849–1857.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations